Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level

doi:10.3748/wjg.v11.i22.3346

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 22

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2405)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

203

HTML

1879

Figures (1-4)

163

Tables (1-2)

160

Sum=2405

Jun 14, 2005 (publication date) through Jul 3, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Jun 14, 2005; 11(22): 3346-3350
Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3346

Full Size Figure Download Figure

Figure 4 Cumulative incidence of HBeAg seroconversion of groups 1 to 4 by Kaplan-Meier method. Group 1 is indicated by thick line, group 2 by dotted line, group 3 by dashed line, and group 4 by thin line. Groups 1 vs 2, P = 0.048; groups 1 vs 3, P = NS; groups 2 vs 3, P = NS (log-rank test).

Citation: Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H. Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol 2005; 11(22): 3346-3350
URL: https://www.wjgnet.com/1007-9327/full/v11/i22/3346.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i22.3346